Troponin is vital in the evaluation of acute coronary syndrome. Decision limits, based on the 99 th percentile upper reference limit derived from a sufficiently large normal reference population, must be determined for each specific troponin method. The new troponins exhibit high-sensitivity performance -assay precision at less than 10% coefficient of variation (at the 99 th percentile upper reference limit) and ability to detect measurable values in healthy subjects. The troponin literature has reached a tipping point necessitating guidance on its use from specialist societies.
INTRODUcTION
Cardiac muscle injury results in the release of biomarkers such as enzymes or proteins, into the bloodstream. Cardiac troponin (cTn) is the preferred biomarker for the evaluation of acute coronary syndromes (ACS). Since the recent review of troponin in this journal 1 , much new data has accrued on troponin that impacts clinical practice. The criteria for the definition of myocardial infarction (MI) 2 have been updated to clarify the occurrence of myocardial necrosis after percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG). Guidance for the use of high-sensitivity (hs) cTn have also been issued [3] [4] [5] . This review will briefly highlight some of these developments and its impact on clinical practice.
DEFINITION OF MYOcARDIAL INFARcTION (MI)
Biochemical markers and imaging can detect the presence of myocardial injury or necrosis. Troponin is the biomarker used for the diagnosis of MI. MI is diagnosed when there is a rise and/or fall in cTn with at least one value above the 99 th percentile (99P) of the upper reference limit (URL) of a healthy population and in clinical settings consistent with acute myocardial ischaemia 2 such as:
• Symptoms of ischaemia • New significant ST-T wave changes or LBBB • Pathological q waves on ECG • New imaging evidence of abnormal wall motion or loss of viable myocardium • Intracoronary thrombus identified by angiography or autopsy Troponin elevation indicates that myocardial necrosis is likely to be present, but by itself is not indicative of an MI [6] [7] [8] . Equally, not all myonecrosis is indicative of ACS even if ischaemia is present. However, increased troponin often carries greater risk for poorer clinical outcomes 9 . Other biomarkers of MI such as myoglobin or CK-MB are no longer needed 4 . In fact, in 21 patients undergoing transcoronary ablation for septal hypertrophy with serial monitoring of cardiac biomarkers in their blood, hs-cTnT was the earliest to increase (15 min), followed by myoglobin (30 min), cTnT (60 min) and CK-MB (90 min) 10 .
Commencing treatment for MI based on an elevated troponin alone could harm the patient. For periprocedural MI, cTn elevation has been set at higher levels -more than five times 99 P URL for PCI and greater than 10 times 99P URL for CABG 2 .
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HIGH-SENSITIVITY cARDIAc TROPONINS (hs-cTn) ASSAYS
Hs-cTn assays are those that detect the presence of troponin in the single digit range of nanograms per litre (ng/L) in a significant proportion of normal individuals. They also allow a more precise determination of the 99P URL of the reference population with a co-efficient of variation (CV) of <10% 11 . This degree of precision increases the likelihood of detecting small changes in serial cTn measurements. Besides, the hs-cTn should demonstrate the presence of detectable troponin levels in the sera of most healthy subjects 11, 12 .
The only available on-market hs-cTn is hs-cTnT (Roche Diagnostics) that is used by many laboratories in Europe and several laboratories in Singapore. Regulatory hurdles have prevented the introduction of hs-cTn in the United States for now. Dickinson) is the preferred sample for analysis as residual platelet, leucocyte or fibrin strands may cause false positive cTn results 13 .
Serum collected in rapid serum tubes (Becton
While it is clear that reference values and decision limits for cTn should be derived from healthy subjects without a history of known cardiac disease 14 , how such a reference population is derived remains undefined. Electrocardiograms (ECG), cardiac imaging (echocardiography, coronary CT, MRI) and serum natriuretic peptides have been suggested for screening out cardiac disease 14 , but these measures will incur more costs.
As more individuals will present to the emergency department with detectable hs-cTn, it is particularly important to compare their troponin levels to a robust cardio-healthy reference population. Determination of the 99 th percentile URL is affected by high-end outliers. Thus a sample size of at least 500 is needed to be 95% certain that 99% of the reference population is below the URL 14 .
Gender differences in cTn have been observed in all the hs-TnT reference range studies as well as in most of the c-TnI studies 1, 8 . Specialist societies of cardiology 4,5 now recognise that sex-dependent reference values may be recommended for hs-cTn assays as is the case with CK-MB. An age-related difference has also been recently emphasised [15] [16] [17] . The impact of using gender-or age-specific cTn limits for the management of ACS has merit in that the use of age-and gender-matched reference values may improve the diagnostic specificity of cTn in the evaluation of ACS.
EARLY DIAGNOSIS OF AMI
The introduction of high-sensitivity (hs) assays for cTn-T and the availability of prototype hs-cTn-I have shown that more subjects with ACS, especially of the non-ST segment elevation variety are diagnosed 1 . These studies demonstrate improved early diagnosis of AMI in unselected patients with acute chest pain. Subjects with preexisting coronary artery disease (CAD) may already have elevated cTn and abnormal ECGs. Evaluation of these patients for possible AMI is challenging as they can ill afford myocardial loss if their diagnosis is delayed. The more sensitive cTn assays also provide high diagnostic accuracy in these patients 18 .
In subjects with chest pain, undetectable hs-cTnT (<3ng/L) has been reported to have a very high negative predictive value (NPV) of 99.4% 19 suggesting its value in ruling out AMI. This study also reported that hs-TnT above the 99P URL (14 ng/L) had a sensitivity of 98.4% and a positive predictive value (PPV) of 92.8% for ruling in AMI. A recent European study has confirmed that acute chest pain subjects with hs-cTnT <14 ng/L can be safely discharged from the emergency department 20 .
IMPROVED RISK STRATIFIcATION
In subjects with chest pain and normal levels of conventional troponin (n=446), undetectable hs-cTnT (<3ng/L) also has a high NPV of 93% 21 .
The universal definition of MI implies at least two serial cTn determinations to establish a kinetic change 2 . Using a 99P URL of 30 ng/L for ruling out AMI, admission hs-TnI (research use only assay) had a sensitivity of 82.3% and a NPV 94.7% while the three-hour hs-TnI had a sensitivity of 98.2% and NPV of 99.4% 22 . This suggests that a serial change (admission to 3 hours) in hsTnI may facilitate an early diagnosis of AMI. Current ACS guidelines now recommend sampling hs-cTn at presentation and three hours later 23 .
A rapid rule-in or rule-out of AMI in the emergency department with baseline hs-cTnT and the absolute change in one-hour hs-cTnT has been reported 24 . AMI was ruled out in subjects with baseline hs-cTnT <12 ng/L and an absolute change <3ng/L; baseline Proceedings of Singapore Healthcare  Volume 21  Number 4  2012 hs-cTnT >52 ng/L or a change over one hour of 5 ng/L ruled in AMI. This algorithm classified 60% of the subjects as rule-out, 17% as rule-in and 23% as observational cases with the corresponding cumulative 30-day survival of 99.8%, 95.3%, and 98.6%, respectively. The low 30-day mortality (0.2%) for those ruled-out for AMI underscores the suitability of such patients for early discharge. A one hour hs-cTnT algorithm has also been used to separate AMI from acute cardiac non-CAD for early coronary angiography 25 . Presentation hs-cTnT <28 ng/L and an absolute change <5 ng/L after one hour served best to exclude ACS patients from urgent angiography.
In the quest to minimise myocardial damage through earlier treatment of AMI, much of the literature has centered on the use of absolute or relative percentage changes of hs-cTn values in serial testing 4 . With hs-cTnT, an absolute increase (>7 ng/L over 2 hours) appears to be superior to a relative percentage change over baseline values.
A single hs-cTnT (>14 ng/L) at seven weeks after an AMI has been shown to have good prognostic value (30-month mortality and/ or AMI), independent of B-type natriuretic peptide (BNP) or echocardiographic evidence of ventricular dysfunction 26 .
OTHER cAUSES OF ELEVATED TROPONIN
In practice, we have to be mindful of the many non-ACS ischaemic (tachyarrhythmia, left ventricular hypertrophy, coronary vasospasm) and nonischaemic (heart failure, pulmonary embolism, chronic kidney disease, sepsis, drug-induced cardiomyopathy) troponin elevations 5 when considering further investigation of possible ACS in these patients. In most cases, they can be resolved through careful history, physical examination and thoughtful differential diagnosis 27 .
HIGH-SENSITIVITY TROPONIN I (hs-cTnI)
As there are no hs-cTnI assays available in the market just now, this literature while interesting is premature for clinical practice. When hs-cTnI 12 assays enter the clinic, their performance will need to be critically evaluated although early indications suggest that they will add to the diagnostic armamentarium 22 .
SUMMARY
The recent documents issued by professional societies re-emphasise:
• MI is defined as a rise or fall in cTn with at least one value above the upper limit of normal in a consistent clinical setting • A single hs-cTnT (>14 ng/L) at seven weeks post-MI has good prognostic value (30-month mortality and/or AMI)
cONcLUSION
In clinical practice, the major challenge in troponin testing is the judicious use of the diagnostic service and not the biomarker per se. All caregivers need to watch the rapidly moving troponin research space diligently to keep pace with the evidence.
